If you had bought Ambev on 26 October 2025, Lula's re-election sell off and the sharp 19% drop that followed would have been fresh in mind, along with analysts debating whether digital expansion or falling alcohol demand would dominate the next few years. Holding Ambev over the past year would have returned 33.9%, including dividends. If that decision were back on the table today, how much weight would you give to Brazil risk versus the company's premium and non-alcoholic push?
The easy part of this move is behind Ambev. Zero in on 195 high quality undervalued stocks for companies trading below our estimates.
The Two Stories Ambev Investors Had In Front Of Them
The shares cost R$12.11 at the start of the period, and anyone looking at Ambev then had to decide which future felt more believable for a Brazil heavy brewer leaning into premium and non-alcoholic drinks.
The bullish view anchored on a Fair Value of R$14.41, a price implied by assumptions like 5.2% annual revenue growth and profit margins reaching 17.3% over about three years as digital platforms and premium lines expanded.
The bearish story pointed to a Fair Value of R$11.3, with investors focused on declining alcohol consumption, tighter rules, and the risk that heavier regulation and competition would cap both volumes and pricing power.
What The Results Changed For The Ambev Debate
Q2 2026 put hard numbers on the Ambev argument. Total revenue reached R$20,148.919m, net income came in at R$3,386.915m, and net margin moved to 16.8% from 13.5%. That tilt in profitability leaned toward the optimistic case that expected stronger earnings power from premium and digital, although the modest top line gain kept the cautious scenario alive.
The hinge assumption here was margin credibility. When a bullish story leans on future profitability, it is important to stress test it against reported net income and margin, quarter by quarter, rather than only watching the share price.
What Ambev's One Year Run Now Asks You To Believe
Ambev trades at R$15.37 after a 33.9% gain over the past year, above where this Narrative's Fair Value sits. The focus now is less on survival questions and more on whether premium, Balanced Choices and Beyond Beer can keep doing the heavy lifting.
Today's price leans on an assumption that premium brands, non-alcoholic offerings and the BEES and Zé Delivery platforms keep margins healthy. The Narrative asks how that holds up if Brazil non-alcoholic volumes stay soft or digital engagement stops translating into enough profitable volume.
"Key Takeaways: Bearish analysts expect Ambev's exposure to Brazil, regulatory risk and currency volatility, combined with underperforming non-alcoholic beverages and softer pockets in core markets, to keep pressuring volumes, mix and the premiumization story. The main condition for Ambev is that its premium, Balanced Choices and Beyond Beer portfolio, together with the BEES and Zé Delivery digital platforms and disciplined cost control, continue to support margin expansion and healthy cash generation despite cyclical beer demand swings and input cost pressure."
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all
Looking Beyond Ambev's Home Turf
Ambev keeps you focused on beer, premium labels and Brazil risk. One step away, a different alcohol story is unfolding for investors.
Spirits and ready to drink products sit at the centre of that narrative. An anonymous business behind them is reshaping its cost base and operating model.
Management there is working to free up cash and trim overheads. It is also planning to expand a high margin stout brand globally.
These moves target more efficient production, leaner inventories and tighter pricing discipline. If they come together, the earnings mix could differ sharply from Ambev's beer heavy profile.
That argument has a Narrative and a number behind it. → See the company one Narrative values 37% above its price
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ABEV3.bovespa .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
